Article Text

Download PDFPDF
Effectiveness of influenza vaccine in TNF inhibitors treated patients: comment on the article by Burmester et al
  1. Giovanni Adami,
  2. Angelo Fassio,
  3. Giovanni Orsolini,
  4. Alessandro Giollo,
  5. Davide Gatti,
  6. Maurizio Rossini
  1. Rheumatology Unit, University of Verona, Verona, Italy
  1. Correspondence to Dr Giovanni Adami, Rheumatology Unit, University of Verona, Verona 37135, Italy; adami.g{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Tumour necrosis factor-α inhibitors (TNFi) are immunosuppressive therapies that are known to increase infectious risk. Indeed, patients affected by TNFi requiring conditions are at higher risk of influenza compared with healthy controls.1 Furthermore, mildly reduced seroconversion rate after influenza vaccination had been reported in TNFi-treated patients.2 Nonetheless, the immune response is considered large enough to recommend influenza vaccination in all patients affected by rheumatoid arthritis, regardless of treatment.3 However, there are data showing that patients are not being vaccinated as recommended.4 In addition, given that subjects with autoimmune conditions treated with TNFi are at higher risk for influenza,1 the …

View Full Text


  • Handling editor Josef S Smolen

  • Contributors All authors contributed equally to the design of the study and write-up of the letter.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.